Cytokinetics Profitability Analysis

CYTK
 Stock
  

USD 52.26  1.28  2.39%   

For Cytokinetics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cytokinetics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cytokinetics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cytokinetics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cytokinetics over time as well as its relative position and ranking within its peers. Continue to Trending Equities.
  
Cytokinetics Price to Sales Ratio is increasing as compared to previous years. The last year's value of Price to Sales Ratio was reported at 49.76. The current Sales per Share is estimated to increase to 0.99, while Return on Sales is projected to decrease to (3.05) . The current Preferred Dividends Income Statement Impact is estimated to increase to about 1.5 M, while Accumulated Other Comprehensive Income is projected to decrease to (891.9 K).

Cytokinetics Revenues

59.29 Million

Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.4 B
Quarterly Revenue Growth YOY
30.29
Return On Assets
-0.17
Return On Equity
-3.38
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Cytokinetics Shares Owned by Institutions vs. Beta Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Cytokinetics's current stock value. Our valuation model uses many indicators to compare Cytokinetics value to that of its competitors to determine the firm's financial worth.
Cytokinetics is number one stock in beta category among related companies. It is number one stock in shares owned by institutions category among related companies producing about  96.73  of Shares Owned by Institutions per Beta. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cytokinetics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cytokinetics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cytokinetics' earnings, one of the primary drivers of an investment's value.

Cytokinetics Shares Owned by Institutions vs. Beta

Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it will be expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Cytokinetics 
Beta 
 = 
Covariance 
Variance 
1.18
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Cytokinetics 
Shares Held by Institutions 
 = 
Funds and Banks 
Firms 
114.14 %
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.

Cytokinetics Shares Owned by Institutions Comparison

Cytokinetics is currently under evaluation in shares owned by institutions category among related companies.

Cytokinetics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Cytokinetics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cytokinetics will eventually generate negative long term returns. The profitability progress is the general direction of Cytokinetics' change in net profit over the period of time. It can combine multiple indicators of Cytokinetics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for 2022
Accumulated Other Comprehensive Income-869 K-891.9 K
Consolidated Income-215.3 M-221 M
Net Income-215.3 M-221 M
Net Income Common Stock-215.3 M-221 M
Operating Income-186.3 M-191.2 M
Preferred Dividends Income Statement Impact1.2 M1.5 M
Net Income Per Employee-586.7 K-633 K
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people.

Cytokinetics Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Cytokinetics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cytokinetics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cytokinetics' important profitability drivers and their relationship over time.

Cytokinetics Profitability Trends

Cytokinetics profitability trend refers to the progression of profit or loss within a business. An upward trend means that Cytokinetics' profit has generally increased over time, and a downward profitability trend means profits are declining. Recognizing problems early in profitability trends allows investors to address revenue and cost issues in advance. Investors and analysts usually monitor three types of profitability trends: gross, operating, and net. Gross profit is the difference between revenue and costs of goods sold. Operating profit is Cytokinetics' gross profit minus its overhead. After you account for other unusual revenue, expenses, and costs, you get net profit. Gross profit trends are often a good indicator of future profitability. If you have high gross profit margins, you have a better chance to cover overhead and make money.

Cytokinetics Profitability Drivers Correlations

One of the toughest challenges investors face today is learning how to quickly synthesize and read into endless financial statements and information provided by the company, SEC reporting, and various external parties. Understanding the correlation between Cytokinetics different financial indicators related to revenue and profit generation helps investors identify and prioritize their investing strategies towards Cytokinetics in a much-optimized way. Analyzing correlations between profit drivers that are directly associated with dollar figures is the most effective way to break down Cytokinetics' future profitability.

Use Cytokinetics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.

Cytokinetics Pair Trading

Cytokinetics Pair Trading Analysis

The ability to find closely correlated positions to Cytokinetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.
The correlation of Cytokinetics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Cytokinetics position

In addition to having Cytokinetics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Hotels Thematic Idea Now

Hotels
Hotels Theme
Hotels, inns, motels, and other companies providing lodging and hospitality services. The Hotels theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hotels Theme or any other thematic opportunities.
View All  Next Launch
Continue to Trending Equities. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
To fully project Cytokinetics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cytokinetics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cytokinetics' income statement, its balance sheet, and the statement of cash flows.
Potential Cytokinetics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Cytokinetics investors may work on each financial statement separately, they are all related. The changes in Cytokinetics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cytokinetics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.